Michael Dechant

Medicine · Health Sciences

27h-index2.3kcitations80works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(53), Glycosylation and Glycoproteins Research(27), Immunodeficiency and Autoimmune Disorders(16), T-cell and B-cell Immunology(14), HER2/EGFR in Cancer Research(14)

Publications80 total

The Systemic Administration of Multipotent Mesenchymal Stroma Cells Alters the Inflammatory Response in the Lung During Murine Polymicrobial Sepsis
SSRN Electronic Journal·2025Open Access
Opioid substitution treatment, relapse and addiction-related outcomes in prison setting and after release: A longitudinal study
Nordic Studies on Alcohol and Drugs·2024· 4 citedOpen Access
Vergleich substituierter und nicht-substituierter opioidabhängiger Strafgefangener in Bezug auf das Verhalten im Haftalltag
Praxis der Rechtspsychologie·2023· 1 cited
Zur Legalbewährung von Opioidabhängigen nach der Entlassung aus der Haft
Praxis der Rechtspsychologie·2023· 1 cited
Supplementary Figure 5 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Supplementary Figure 2 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Supplementary Legends of Tables 1-2, Figures 1-5 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Supplementary Figure 3 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Supplementary Legends of Tables 1-2, Figures 1-5 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Data from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Supplementary Figure 1 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Supplementary Figure 2 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Supplementary Table 1 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Supplementary Table 2 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Supplementary Figure 1 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Supplementary Figure 4 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Supplementary Figure 3 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Supplementary Figure 5 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Supplementary Table 2 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
Supplementary Figure 4 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Thomas Valerius(39), Matthias Peipp(29), Jan G. J. van de Winkel(20), Paul W.H.I. Parren(15), Thomas Beyer(14), Stefan Lohse(14), Tanja Schneider‐Merck(12), Jeroen J. Lammerts van Bueren(11), Sven Berger(11), Stefanie Derer(11), Wim K. Bleeker(9), Roland Repp(9), Martin Gramatzki(9), Christian Kellner(8), Bernhard Stockmeyer(7), Wencke Weisner(6), Jeanette H.W. Leusen(6), Katja Klausz(6), Thomas Beyer(5), Klara Boksán(5)